2026-2034年全球胃食道逆流症治療市場規模、佔有率、趨勢及成長分析報告

預計胃食道逆流症 (GERD) 治療市場規模將從 2025 年的 58.3 億美元成長到 2034 年的 75.6 億美元，2026 年至 2034 年的複合年成長率為 2.93%。

由於全球胃酸逆流和胃腸道疾病的發生率不斷上升，胃食道逆流（GERD）治療藥物的全球市場正經歷著穩定成長。久坐的生活方式、不健康的飲食習慣、肥胖和壓力是導致GERD病例增加的主要因素。包括質子幫浦阻斷劑（PPI）和H2受體拮抗劑在內的有效藥物的日益普及，正在推動市場需求的穩定成長。

關鍵成長要素包括診斷程序的改進、醫療保健意識的提高以及非處方藥的普及。製藥公司正投資研發緩釋製劑和聯合治療，以提高治療效果。已開發國家和開發中國家醫療基礎設施的擴建以及老年人口的成長，也為市場進一步成長提供了支持。

未來，隨著新藥製劑的研發和微創治療方法的進步，市場預計將持續擴張。標靶治療的研究以及提高患者依從性的措施將有助於提升治療效果。新興市場醫療保健服務的普及和公眾意識的提高，預計將為胃食道逆流（GERD）治療藥物生產商創造巨大的發展機會。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球胃食道逆流症治療市場：依藥物類別分類

• 市場分析、洞察與預測
• 質子幫浦阻斷劑（PPI）
• H2受體拮抗劑（H2RAs）
• 制酸劑
• 胃腸動力促效劑
• 其他藥物類別

第5章 全球胃食道逆流症（GERD）治療市場：依給藥途徑分類

• 市場分析、洞察與預測
• 口服
• 注射藥物

第6章：全球胃食道逆流症治療市場：依階段分類

• 市場分析、洞察與預測
• 第一階段
• 第二階段
• 第三階段
• 第四階段

第7章 全球胃食道逆流症治療市場：依分銷管道分類

• 市場分析、洞察與預測
• 醫院藥房
• 零售藥房
• 網路藥房

第8章 全球胃食道逆流症治療市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • AstraZeneca
  • Camber Pharmaceuticals
  • Eisai
  • Johnson & Johnson
  • Onconic Therapeutics
  • Pfizer
  • Phathom Pharmaceuticals
  • Sebela Pharmaceuticals
  • Takeda Pharmaceutical Company
  • Teva Pharmaceuticals
  • Viatris

The Gastroesophageal Reflux Disease Therapeutics Market size is expected to reach USD 7.56 Billion in 2034 from USD 5.83 Billion (2025) growing at a CAGR of 2.93% during 2026-2034.

The Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market is witnessing steady growth due to increasing incidence of acid reflux and digestive disorders globally. Sedentary lifestyles, unhealthy eating habits, obesity, and stress are major contributors to rising GERD cases. The growing availability of effective medications, including proton pump inhibitors (PPIs) and H2 receptor antagonists, is driving consistent demand.

Key growth drivers include improved diagnostic procedures, growing healthcare awareness, and easy availability of over-the-counter medications. Pharmaceutical companies are investing in extended-release and combination therapies to enhance treatment outcomes. Expanding healthcare infrastructure and rising geriatric populations in both developed and developing regions are further supporting market growth.

In the future, the market is expected to expand with the development of novel drug formulations and minimally invasive treatment options. Research into targeted therapies and improved patient compliance strategies will strengthen treatment effectiveness. Emerging markets with increasing healthcare access and awareness are projected to create significant opportunities for GERD therapeutic manufacturers.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• Proton Pump Inhibitors (PPIs)
• H2 Receptor Antagonists (H2RAs)
• Antacids
• Prokinetic Agents
• Other Drug Classes

By Route of Administration

• Oral
• Injectable

By Stage

• Stage 1
• Stage 2
• Stage 3
• Stage 4

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• AstraZeneca, Camber Pharmaceuticals, Eisai, Johnson Johnson, Onconic Therapeutics, Pfizer, Phathom Pharmaceuticals, Sebela Pharmaceuticals, Takeda Pharmaceutical Company, Teva Pharmaceuticals, Viatris
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Proton Pump Inhibitors (PPIs) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. H2 Receptor Antagonists (H2RAs) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Antacids Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Prokinetic Agents Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Other Drug Classes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Route Of Administration
• 5.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET: BY STAGE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Stage
• 6.2. Stage 1 Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Stage 2 Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Stage 3 Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Stage 4 Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Drug Class
  • 8.2.2 By Route Of Administration
  • 8.2.3 By Stage
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Drug Class
  • 8.3.2 By Route Of Administration
  • 8.3.3 By Stage
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Drug Class
  • 8.4.2 By Route Of Administration
  • 8.4.3 By Stage
  • 8.4.4 By Distribution Channel
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Drug Class
  • 8.5.2 By Route Of Administration
  • 8.5.3 By Stage
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Drug Class
  • 8.6.2 By Route Of Administration
  • 8.6.3 By Stage
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 AstraZeneca
  • 10.2.2 Camber Pharmaceuticals
  • 10.2.3 Eisai
  • 10.2.4 Johnson & Johnson
  • 10.2.5 Onconic Therapeutics
  • 10.2.6 Pfizer
  • 10.2.7 Phathom Pharmaceuticals
  • 10.2.8 Sebela Pharmaceuticals
  • 10.2.9 Takeda Pharmaceutical Company
  • 10.2.10 Teva Pharmaceuticals
  • 10.2.11 Viatris